<DOC>
	<DOCNO>NCT00917267</DOCNO>
	<brief_summary>Previous study suggest once-weekly formulation exenatide may provide sustained glycemic control . These previous study exenatide weekly conduct non-Asian population , study develop support local regulatory requirement China , Korea , Japan , India , Taiwan .</brief_summary>
	<brief_title>A Study Examine Effects Exenatide Once-Weekly Injection Glucose Control Safety Asian Subjects</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Exenatide</mesh_term>
	<criteria>Have diagnose type 2 diabetes . Have suboptimal glycemic control evidence HbA1c 7.1 % 11.0 % inclusive . Have body mass index ( BMI ) &gt; 21 kg/m2 &lt; 35 kg/m2 , inclusive . Have history stable body weight ( vary &gt; 5 % least 90 day prior study start ) . Have treat stable dose regimen Met , SU , TZD , Met plus SU , Met plus TZD , SU plus TZD least 90 day prior study start . Have contraindication OAD ( ) use . Have know allergy hypersensitivity exenatide BID , exenatide QW , excipients contain agent . Have receive chronic &gt; 14 consecutive day ) systemic glucocorticoid therapy oral , intravenous ( IV ) , intramuscular ( IM ) route intraarticular steroid injection within 4 week prior study start regularly treat potent , inhaled steroid know high rate systemic absorption . Have treat drug promote weight loss ( example , GLP1 analogue , orlistat , sibutramine , phenylpropanolamine , similar overthecounter medication ) within 90 day study start . Have treat &gt; 2 week follow excluded medication within 90 day prior study start : Insulin Dipeptidyl peptidase ( DPP ) 4 inhibitor ( example , sitagliptin vildagliptin ) Pramlintide acetate Drugs directly affect gastrointestinal motility , include , limited : Reglan® ( metoclopramide ) , Propulsid® ( cisapride ) , chronic macrolide antibiotic . Have prior exposure exenatide Have previously complete withdrawn study study investigate exenatide BID QW . Have receive treatment within last 30 day drug receive regulatory approval indication time study entry . Are currently enrol clinical study .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>diabetes</keyword>
	<keyword>exenatide</keyword>
	<keyword>weekly</keyword>
	<keyword>Byetta</keyword>
	<keyword>Amylin</keyword>
	<keyword>Lilly</keyword>
</DOC>